EPIRUS Biopharmaceuticals Expands Biosimilar Pipeline and Capabilities Through Acquisition of Bioceros
09 sept. 2015 06h00 HE
|
EPIRUS Biopharmaceuticals, Inc.
Combined companies’ product pipeline targets reference biologics with sales of $29 billion in 2014Pipeline expanded to include biosimilars to Soliris®, STELARA® and SIMPONI® Capabilities...